Health AI Central
Share:
Peer-Reviewed Publication
Pathology2026;58(6):737-739.October 1, 2026Letter

BRCA1-mutant thymoma and the role of PARP inhibitors: a case report.

Joey Yan Leng Tan1, Jeanette Yuen2, Joanne Ngeow3, Wen Yee Chay4, Francis Hong Xin Yap5
1Department of Anatomical Pathology, Singapore General Hospital, Singapore. Electronic address: joey.tanyl@mohh.com.sg.
2Cancer Genetics Service, Division of Medical Oncology, National Cancer Centre Singapore, Singapore.
3Cancer Genetics Service, Division of Medical Oncology, National Cancer Centre Singapore, Singapore; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.
4Department of Medical Oncology, National Cancer Centre Singapore, Singapore.
5Department of Anatomical Pathology, Singapore General Hospital, Singapore.
PubMed DOI

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.